Allocentric Memory in MS and Resting State Functional MRI

Allocentric Memory as a Novel Measure of Cognitive Inefficiency: Sensitivity in Multiple Sclerosis (MS) Subjects and Relationship With Resting State Functional MRI

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02118298

Enrollment

120

Registered

2014-04-21

Start date

2014-04-30

Completion date

2016-04-30

Last updated

2016-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The goals of this study are to 1. Investigate the sensitivity of allocentric visual memory when compared to more established measures of cognition in identifying cognitive difficulties among MS subjects when compared to controls. 2. Determine which cognitive test variable will be most strongly associated with self and informant reports of cognition. 3. Determine which MRI metric will be most strongly related to neuropsychological test performance 4. Determine the degree to which allocentric visual memory is related to functional connectivity on fMRI.

Detailed description

This is a cross-sectional, case-control, observational experimental design. The study will enroll subjects with multiple sclerosis (MS) and age/gender matched on a battery of neuropsychological cognitive tests and self-report measures of cognition.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* 18-55 years old * Right handed * Capacity to provide informed consent and sign consent * Diagnosis of Relapsing Remitting MS that meets the revised McDonald Criteria (2010) within the last 10 years * EDSS 0- 5.5

Exclusion criteria

* Diagnosis of primary progressive MS * Contraindications for MRI * Subjects required to take medications known to either benefit or adversely affect cognition at the time of testing and impact neuroimaging * Non-MS neurological disorders * Other medical or psychiatric disorders likely to affect cognitive performance * Active immunodeficiency, chronic infections, or history or progressive multifocal leukoencephalopathy * Individuals with severe level of depression on the BDI-II or severe anxiety on the BAI * MS subjects who are actively experiencing acute exacerbation in symptoms and they must be at least 4 weeks free of steroid medication, are currently taking a chemotherapy agent, or have changed medication in the last two months * Subjects who fail symptom validity measures during neuropsychological testing will be excluded

Design outcomes

Primary

Measure	Time frame	Description
Minimal Assessment of Cognitive Function in MS (MACFIMS)	Baseline	The MACFIMS is composed of seven neuropsychological tests, covering five cognitive domains commonly impaired in MS (processing speed/working memory, learning and memory, executive function, visual-spatial processing and word retrieval)

Countries

United States

Outcome results